Apogee Therapeutics (APGE) Expected to Announce Earnings on Monday

Apogee Therapeutics (NASDAQ:APGE) is anticipated to issue its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($1.05) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:00 PM ET.

Apogee Therapeutics Trading Down 0.8%

Shares of NASDAQ APGE opened at $68.39 on Monday. The company has a market capitalization of $4.67 billion, a price-to-earnings ratio of -15.61 and a beta of 1.42. Apogee Therapeutics has a twelve month low of $26.20 and a twelve month high of $84.56. The business has a 50 day simple moving average of $73.68 and a 200-day simple moving average of $58.60.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Royal Bank Of Canada cut shares of Apogee Therapeutics from an “outperform” rating to a “sector perform” rating and increased their target price for the stock from $70.00 to $83.00 in a report on Thursday, January 22nd. BTIG Research set a $137.00 price objective on shares of Apogee Therapeutics in a research report on Tuesday, January 6th. Wolfe Research started coverage on shares of Apogee Therapeutics in a report on Wednesday, January 7th. They issued a “peer perform” rating on the stock. UBS Group raised Apogee Therapeutics to a “strong-buy” rating in a report on Wednesday, January 7th. Finally, Wall Street Zen cut Apogee Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Apogee Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $104.58.

Insider Activity

In other Apogee Therapeutics news, Director Fairmount Funds Management Llc sold 1,750,000 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $76.30, for a total value of $133,525,000.00. Following the completion of the sale, the director directly owned 298,647 shares in the company, valued at $22,786,766.10. This represents a 85.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Michael Thomas Henderson sold 40,000 shares of the company’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $75.01, for a total value of $3,000,400.00. Following the completion of the sale, the chief executive officer owned 1,232,987 shares of the company’s stock, valued at approximately $92,486,354.87. This trade represents a 3.14% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 1,885,100 shares of company stock valued at $143,557,153. Company insiders own 42.77% of the company’s stock.

Institutional Trading of Apogee Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in APGE. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Apogee Therapeutics by 189,522.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company’s stock valued at $206,246,000 after purchasing an additional 2,731,015 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Apogee Therapeutics by 142.6% during the fourth quarter. Invesco Ltd. now owns 70,687 shares of the company’s stock valued at $5,335,000 after acquiring an additional 41,549 shares during the period. Vident Advisory LLC purchased a new stake in shares of Apogee Therapeutics in the 4th quarter valued at approximately $218,000. XTX Topco Ltd boosted its stake in Apogee Therapeutics by 225.1% in the 4th quarter. XTX Topco Ltd now owns 19,026 shares of the company’s stock worth $1,436,000 after purchasing an additional 13,174 shares during the period. Finally, Vestal Point Capital LP grew its position in Apogee Therapeutics by 29.4% during the 4th quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock worth $41,514,000 after purchasing an additional 125,000 shares in the last quarter. 79.04% of the stock is currently owned by institutional investors.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.